MedTrace Logo

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

NCT04964388 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-06-13

Study results available
· View outcomes & findings →

Summary

This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)

Conditions

  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2

Interventions

DRUG

GLP-1 receptor agonist

Diabetes medication

Sponsors & Collaborators

  • University of Mississippi Medical Center

    lead OTHER

Principal Investigators

  • Vishnu V Garla, MD · University of Mississippi Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2023-05-01
Completion
2023-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964388 on ClinicalTrials.gov